Acthar Gel

DRUG16 trials

Sponsors

Columbia University, Aaron Miller, Tanner Foundation for Multiple Sclerosis, Ohio State University, Dana Ascherman

Conditions

Arthritis, RheumatoidEnd Stage Renal DiseaseIdiopathic Focal Segmental GlomerulosclerosisLupus Erythematosus, SystemicLupus NephritisMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingPanuveitis

Phase 1

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

TerminatedNCT02486744

Youngstown State UniversityEnd Stage Renal Disease

Start: 2015-03-31End: 2016-07-31Updated: 2017-02-10

Phase 4

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

CompletedNCT01129284

Columbia UniversityTreatment Resistant Nephrotic Syndrome

Start: 2009-12-31End: 2011-09-30Updated: 2014-04-24

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

WithdrawnNCT01926054

Ohio State UniversitySLE Glomerulonephritis Syndrome, WHO Class V

Start: 2013-07-31End: 2018-02-28Updated: 2018-05-11

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

University of CincinnatiPulmonary Sarcoidosis, Sarcoidosis

Start: 2014-06-30End: 2017-09-30Target: 20Updated: 2015-12-08

ACTHar in the Treatment of Lupus Nephritis

TerminatedNCT02226341

Columbia UniversityLupus Nephritis

Start: 2014-10-31End: 2024-01-03Updated: 2025-03-07

Use of CXCL9 as a Biomarker of Acthar Efficacy

RecruitingNCT02523092

University of California, San FranciscoSarcoidosis

Start: 2022-11-03End: 2026-12-31Target: 14Updated: 2023-05-11

Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

TerminatedNCT02546492

University of Maryland, BaltimoreTransplant Glomerulopathy

Start: 2016-08-31End: 2021-05-27Updated: 2022-10-06

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

CompletedNCT02633046

Mallinckrodt ARD LLCIdiopathic Focal Segmental Glomerulosclerosis

Start: 2016-10-10End: 2020-08-27Updated: 2021-08-04

Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

CompletedNCT02919761

MallinckrodtArthritis, Rheumatoid

Start: 2016-11-07End: 2019-02-13Updated: 2020-03-31

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

CompletedNCT02953821

MallinckrodtLupus Erythematosus, Systemic

Start: 2016-12-16End: 2019-10-25Updated: 2020-08-20

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

TerminatedNCT03126760

Mallinckrodt ARD LLCMultiple Sclerosis, Relapsing-Remitting

Start: 2017-05-22End: 2020-07-14Updated: 2021-07-12

Acthar Gel in Participants With Pulmonary Sarcoidosis

CompletedNCT03320070

MallinckrodtSarcoidosis, Pulmonary

Start: 2018-02-21End: 2021-11-15Updated: 2023-02-27

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

TerminatedNCT03656692

MallinckrodtPanuveitis, Uveitis, Intermediate, Uveitis, Posterior

Start: 2018-10-05End: 2020-07-14Updated: 2021-08-03

Unknown Phase

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

Aaron MillerMultiple Sclerosis

Start: 2013-07-31End: 2018-03-31Target: 10Updated: 2017-09-06

Comprehensive Analysis of Relapse in Multiple Sclerosis

Tanner Foundation for Multiple SclerosisMultiple Sclerosis

Start: 2013-08-31End: 2015-01-31Target: 20Updated: 2013-08-01

ACTH Gel Therapy in Rheumatoid Arthritis

CompletedNCT02030028

Dana AschermanRheumatoid Arthritis

Start: 2014-11-30End: 2022-06-30Updated: 2023-09-06

Related Papers

Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis.

2023-10-171 citations

Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.

2023-04-1910 citations

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus

Rheumatology and Therapy2021-09-036 citations

Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar<sup>®</sup> Gel) for Persistently Active Systemic Lupus Erythematosus.

2021-03-099 citations

Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

2020-09-2915 citations

Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis.

2020-06-168 citations

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.

2020-03-1724 citations

Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.

2012-06-1962 citations